Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients?
|
|
- Paula Marian Reed
- 5 years ago
- Views:
Transcription
1 DOI: /jdv JEADV ORIGINAL ARTICLE Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients? A. Langenbruch,* M.A. Radtke, M. Gutknecht, M. Augustin Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany *Correspondence: A. Langenbruch. Abstract Background The Dermatology Life Quality Index (DLQI) is the most frequently used health-related quality of life (HRQoL) instrument for skin diseases. According to the DLQI instructions, the responses not relevant and my skin problem has not at all affected this aspect of life ( not at all ) have to be scored as 0 = no HRQoL impairments. Objective The aim of this study was to estimate potential bias of DLQI measurements for patients with psoriasis based on items considered to be not relevant. Methods One thousand two hundred forty-three patients with psoriasis were surveyed in a cross-sectional study. Disease severity (Psoriasis Area and Severity Index, PASI) and subjective health state (EuroQoL Visual Analogue Scale, EQ VAS) were compared per DLQI item between patients who answered the respective question not relevant and those who answered not at all. Results Patients who declared a DLQI item to be not relevant showed a higher disease severity and a lower health state. Conclusion Results indicate that patients who declare a DLQI item to be not relevant have a higher disease-related burden than those who do not feel affected by their psoriasis in the same aspect of life. If aspects of life are considered to be not relevant due to high disease burden, this should be reflected by a HRQoL instrument. Received: 5 April 2018; Accepted: 14 August 2018 Conflicts of Interest Anna Langenbruch and Mandy Gutknecht declare no conflicts of interest. Marc Alexander Radtke has received research grants and/or consulting or lecturing fees from AbbVie, Almirall, Amgen, Astellas, Biogen, Biologix, B ohringer, Celgene, Eli Lilly, Galderma, Hexal, Janssen-Cilag, La Roche Posay, Leo, Medac, Merck, MSD, Mundipharma, Novartis, Pfizer, Sandoz, and Sanofi. Matthias Augustin has received research grants and/or consulting or lecturing fees from AbbVie, Almirall, Amgen, Astellas, Biogen, Biologix, B ohringer, Celgene, Eli Lilly, Galderma, Hexal, Janssen-Cilag, La Roche Posay, Leo, Medac, Merck, MSD, Mundipharma, Novartis, Pfizer, Sandoz, and Sanofi. Funding Source Biogen provided financial support for this study. Introduction In past decades, health-related quality of life (HRQoL) has become a major outcomes parameter in dermatology. As recommended by regulatory authorities, measurement of HRQoL is included in almost all clinical trials. 1,2 In clinical care, the use of patient-relevant outcomes has likewise been recommended by guidelines and consensus documents. 3,4 Recommendations for the use of HRQoL instruments have been issued. 5 The Dermatology Life Quality Index (DLQI) has become the most frequently used disease-specific quality of life instrument for skin diseases It has gained high acceptance due to good feasibility and ease of use. Moreover, an anchor-based system of severity classification has been developed, and attempts to establish minimum clinically important differences have been made. 11 However, some drawbacks of the DLQI have been discussed and need to be taken into account Moreover, there are obviously limitations with respect to content validity when indications other than chronic inflammatory skin diseases are investigated. Another potential limitation is its construction as a sum scored HRQoL instrument combined with the fact that missing values and items marked as not relevant are scored as 0 = no
2 124 Langenbruch et al. impairment. Hence, patients who mark an item as not relevant, which is an option in 8 out of 10 items, are considered to be unaffected in that aspect of life. This raises the question whether there are disease-related reasons for considering an item to be not relevant. This could be related to being too impaired by the skin disease to take part in certain areas of life. If so, patients would be ascribed a lower overall DLQI score (=higher HRQoL) in the absence of the corresponding HRQoL. A potential bias in the DLQI score arising from this aspect has not yet been systematically analysed in the literature. Hence, the current study was conducted in a large cohort of psoriasis patients in order to assess the extent of bias that may result from the technical construction of the DLQI, specifically in terms of the treatment of not relevant declarations. The research questions were as follows: 1 What is the proportion of psoriasis patients with missing answers and items declared to be not relevant? 2 Are there any differences with respect to severity indicators between psoriasis patients who state not relevant and those who state my skin problem has not at all affected this aspect of life over the last week ( not at all ) for particular DLQI items? Methods Study design Data were obtained from a large cross-sectional nationwide study conducted with adult patients with psoriasis vulgaris in dermatological care in Germany. 15 Data collection took place between January 2013 and March Patient-related outcomes were gathered by means of questionnaires with both practitioner and patient components. Outcomes Like the other instruments, the DLQI was used in a validated German translation. 16 Based on ten questions about the impact of the skin disease and its treatment on different aspects of the patient 0 s HRQoL over the last week, the DLQI sum score is calculated by summing up the score of each item. Questions are scored on a four-point Likert scale: 0, not at all/not relevant; 1, a little; 2, a lot; and 3, very much. The total DLQI sum score can range from 0 to 30, with lower scores indicating better HRQoL. The patient 0 s subjective health state was measured by means of the German version of the visual analogue scale (EQ VAS) of the EQ-5D 17 in which the patient assesses his/her own current health state on a scale from 0 ( worst imaginable health state ) to 100 ( best imaginable health state ). Severity of psoriasis was measured by means of the German version of Psoriasis Area and Severity Index (PASI). 18 This score combines the severity ratings of three target symptoms (erythema, infiltration and desquamation) and the involvement of the four main body areas (head, trunk, upper and lower extremities). The PASI score ranges from 0 to 72. Higher scores indicate higher severity of the psoriasis. Statistical analysis All data were described with standard statistical parameters (frequencies for categorical data; mean value and standard deviation for continuous data). Means of two groups were compared by unpaired t-tests. Differences with a probability of a type I (a) error of 0.05 were considered as statistically significant in all analyses. Each unpaired t-test was supplemented by effect-size determination (Cohen s d). It is determined by calculating the mean difference between two groups and divided by the pooled standard deviation. According to Cohen, sizes of 0.2, 0.5 and 0.8, respectively, represent weak, medium and strong effects in unpaired t-tests. 19 The analysis was performed using SPSS Statistics 23 for Microsoft Windows (IBM Corp, Armonk, NY, USA). Results Overall, n = 1243 patients with psoriasis from 82 dermatological centres were included. Mean age was 52 years; proportion of female patients was 43.4% (Table 1). 6.0% of the patients had at least one missing value in the DLQI. By contrast, the proportion of items declared not relevant was considerable (Fig. 1). The items most frequently marked as not relevant were item 7 ( work and study, 28.1%), item 6 ( sport, exercise, 26.0%), item 9 ( sexual relationships, 22.1%) and item 8 ( personal relationships, 15.8%). Overall, 48.7% of patients answered all 10 items without not relevant statements or missing answers. By contrast, the proportion of patients with at least one item declared to be not relevant was 48.0% (1 3 items considered not relevant : 36.1%; >3: 11.9%) (Fig. 2). Subjective health (EuroQoL Visual Analogue Scale, EQ VAS) and disease severity (Psoriasis Area and Severity Index, PASI) differed between patients who stated not relevant and those who stated not at all regarding the same DLQI item. Except for Table 1 Characteristics of the 1243 participating patients with psoriasis Age (years, mean SD) % female 43.4 BMI (mean SD) % obese patients (BMI >30) 30.6 % at least one family member affected by psoriasis 38.0 Disease duration (years, mean SD) DLQI (mean SD) % DLQI > PASI (mean SD) EQ VAS (mean SD) BMI, body mass index; DLQI, Dermatology Life Quality Index; EQ VAS, EuroQoL Visual Analogue Scale; PASI, Psoriasis Area and Severity Index; SD, standard deviation.
3 Underestimation of psoriasis burden by DLQI Over the last week, how itchy, sore, painful or stinging has your skin been? 2. Over the last week, how embarrassed or self conscious have you been because of your skin? 3. Over the last week, how much has your skin interfered with you going shopping or looking after your home or garden? 4. Over the last week, how much has your skin influenced the clothes you wear? 5. Over the last week, how much has your skin affected any social or leisure activities? 6. Over the last week, how much has your skin made it difficult for you to do any sport? 7. Over the last week, has your skin prevented you from working or studying? 8. Over the last week, how much has your skin created problems with your partner or any of your close friends or relatives? 9. Over the last week, how much has your skin caused any sexual difficulties? 10. Over the last week, how much of a problem has the treatment for your skin been, for example by making your home messy, or by taking up time? % Missing Not relevant Relevant Figure 1 Frequencies of missing answers and not relevant statements for each Dermatology Life Quality Index (DLQI) item (n = 1243 patients with psoriasis) % items not relevant Figure 2 Distribution of patients by number of Dermatology Life Quality Index (DLQI) items answered not relevant (n = 1243). the PASI difference between patients answering item 4 ( clothing ), patients who declared a DLQI item to be not relevant displayed a higher disease severity and a lower subjective health (Table 2). Discussion The objective of the present study was to identify a potential bias of the Dermatology Life Quality Index in the outcomes measurement of disease-specific HRQoL in psoriasis as a consequence of items declared to be not relevant. This questionnaire is the most frequently used instrument for the assessment of quality of life in skin diseases worldwide. Accordingly, any potential bias associated with its use is of great interest. Unlike formal validity, which has been described in a number of previous studies, 6 no systematic investigations have been conducted analysing the robustness of the instrument with respect to relevant scaling properties, such as the treatment of items declared to be not relevant. Many regulatory bodies and reimbursement agencies require the DLQI as a measure of patient burden. In many countries, a DLQI >10 is the qualifying threshold for the indication of systemic treatment. Moreover, the benefit assessment for systemic drugs largely depends on effectiveness in patients with moderate to severe disease, defined in the field of psoriasis as DLQI and body surface area (BSA) or PASI >10. 3 Hence, any uncertainty in achieving PASI >10 directly impacts reimbursement, treatment indication and access to drugs for patients under real-world conditions. Owing to the use of a sum score built of 10 items that includes 8 items with a not relevant option that is scored as 0 = no impairment, any item missing or declared to be not relevant for reasons other than a lack of disease burden may prejudice fair HRQoL assessments. The present data for psoriasis support the previous findings of good feasibility and acceptability of the DLQI questionnaire. 8,20 By contrast, the high proportion of patients declaring not relevant at least once in the DLQI indicates that this is not a negligible phenomenon. The largest number of not relevant responses was found for the questions on impairment in work and school, sport, sexual relationships, as well as in social activities. Hence, persons with a lack of social contacts, sexual activity and employment, who rate those items as not relevant because they do not experience those areas of life show a lower quality of life burden according to the DLQI. However, this is precisely the
4 126 Langenbruch et al. Table 2 EQ VAS and PASI of patients responding to particular DLQI items not relevant vs. my skin problem has not affected this aspect of my life over the last week ( not at all ) DLQI item no Subject Patients statement PASI EQ VAS n Mean SD P-value d 1 n Mean SD P-value d 1 3 Daily routines not at all not relevant Clothing not at all not relevant Social and leisure not at all not relevant Sport, exercise not at all not relevant Work, study not at all not relevant Personal relationships not at all not relevant Sexual relationships not at all not relevant Treatment not at all not relevant DLQI, Dermatology Life Quality Index; EQ VAS, EuroQoL Visual Analogue Scale; PASI, Psoriasis Area and Severity Index; SD, standard deviation; 1 effect size. population known to be at high risk of psoriasis and related negative impacts on their life. Hence, the presumed underestimation would most likely affect a group that is actually affected by a high disease burden. This interpretation is supported by the finding that the disease-related burden in patients with psoriasis stating not relevant is higher than that of patients stating my skin problem has not at all affected this aspect of life in most of the DLQI items with a not relevant option. This comparison is of particular interest because both statements are treated the same manner, by scoring them 0 (= no impairment ) for each item, according to the DLQI instructions. A possible limitation of this study is that the specific phrasing of the response options in a specific language may influence how patients respond, which in turn may have a (probably small) bearing whether these results from a German study can be generalized to other language versions of the DLQI instrument. This question should be addressed in future studies. Taken together, the data suggest that considering an item to be not relevant because of disease-related disabilities to participate in sports, social events and other activities of everyday life should be treated differently in HRQoL assessment undertaken by means of DLQI. We also recommend the development of further methodology for HRQoL assessment that can be unambiguously applied to all patients with a given skin disease. Acknowledgements The authors wish to thank all participating centres, the German Psoriasis Network (PsoNet) and the Professional Association of German Dermatologists (BVDD) and the German Society of Dermatology (DDG) for their cooperation in this study. We also thank Biogen for providing financial support to this study. References 1 Committee for Medicinal Products for Human Use (CHMP). Reflection paper on the regulatory guidance for the use of Health-Related Quality of Life (HRQL) measures in the evaluation of medicinal products. European Medicines Agency (EMEA). London, URL ropa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_ jsp&%3Bmid=WC0b01ac ec4 (last accessed: 2 October 2017). 2 U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006; 4: Mrowietz U, Kragballe K, Reich K et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: Schmitt J, Spuls P, Boers M et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy 2012; 67: Prinsen CA, de Korte J, Augustin M et al. Measurement of health-related quality of life in dermatological research and practice: outcome of the EADV Taskforce on Quality of Life. J Eur Acad Dermatol Venereol 2013; 27: Basra MKA, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index : a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159: Finlay AY. Current severe psoriasis and the Rule of Tens. Br J Dermatol 2005; 152: Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:
5 Underestimation of psoriasis burden by DLQI Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 2005; 125: Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol 2002; 147(Suppl. 62): Basra MKA, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology 2015; 230: McKenna SP, Meads DM, Doward LC. Scaling properties of the Dermatology Life Quality Index (DLQI). Value Health 2004; 7: Nijsten T, Meads DM, McKenna SP. Dimensionality of the Dermatology Life Quality Index (DLQI): a commentary. Acta Derm Venereol 2006; 86: Twiss J, Meads DM, Preston EP, Crawford SR, McKenna SP. Can we rely on the Dermatology Life Quality Index as a measure of the impact of psoriasis or atopic dermatitis? J Invest Dermatol 2012; 132: Langenbruch A, Radtke MA, Jacobi A et al. Quality of psoriasis care in Germany: results of the national health care study PsoHealth3. Arch Dermatol Res 2016; 308: Augustin M, Zschocke I, Lange S, Seidenglanz K, Amon U. Lebensqualit at bei hauterkrankungen: vergleich verschiedener Lebensqualit ats-frageb ogen bei psoriasis und atopischer dermatitis [Quality of life in skin diseases: methodological and practical comparison of different quality of life questionaires in psoriasis and atopic dermatitis]. Hautarzt 1999; 50: Brooks R. EuroQol: the current state of play. Health Policy 1996; 37: Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157: Cohen J. The Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Lawrence Erlbaum Associates, Hillsdale, NJ, Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004; 9:
Evaluating Psoriasis: Patient Reported Outcomes and Impact of Disease
Evaluating Psoriasis: Patient Reported Outcomes and Impact of Disease Bruce E. Strober, MD, PhD Professor and Chair Department of Dermatology University of Connecticut Farmington, Connecticut DISCLOSURE
More informationSymptom Severity, Quality of Life and Work Productivity of US Psoriasis Patients During Periods of Flare and Remission
Symptom Severity, Quality of Life and Work Productivity of US Psoriasis Patients During Periods of Flare and Remission 93 Korman, NJ 1, Zhao, Y 2, Roberts, J 3 Pike, J 3, Lu, J 2, Tran, MH 2 (Please see
More informationP4081 Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling
P4081 Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling Mark Lebwohl, 1 Andrew Blauvelt, 2 Matthias Augustin, 3 Yang Zhao, 4 Isabelle Gilloteau,
More informationQuality of life. Community Dermatology. Professor Andrew Y Finlay CBE, FRCP
Community Dermatology Quality of life Professor Andrew Y Finlay CBE, FRCP Department of Dermatology and Wound Healing Cardiff University School of Medicine, Cardiff, UK Address for correspondence: 19 The
More informationDLQI (ESTEEM
192 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis: Pruritus and DLQI Correlations at Week 16 (ESTEEM 1 and 2) Steven R. Feldman, MD, PhD 1 ; Diamant
More informationDermatology Life Quality Index: Data from Danish Inpatients and Outpatients
Acta Derm Venereol 2000; 80: 272±276 CLINICAL REPORT Dermatology Life Quality Index: Data from Danish Inpatients and Outpatients ROBERT ZACHARIAE 1, CLAUS ZACHARIAE 2, HANS IBSEN 3, JANNE TOUBORG MORTENSEN
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Characterization of Disease Burden, Comorbidities and Use of Patients with Psoriasis at Enrollment: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo
More informationPASI 90/100, DLQI 0/1, and IL-17 Receptor/Cytokine: Does it Make a Difference and Are We Ambitious Enough?
PASI 90/100, DLQI 0/1, and IL-17 Receptor/Cytokine: Does it Make a Difference and Are We Ambitious Enough? This symposium took place on 14 th September 2018, as part of the 27 th European Academy of Dermatology
More informationSummer AAD Summer AAD Support provided by LEO Pharma A/S. Poster nº
Support provided by LEO Pharma A/S Fixed combination calcipotriene plus betamethasone dipropionate aerosol foam provides improvement in quality of life and rapid relief of itch/itch-related sleep loss
More informationEffect of Apremilast on Patient-Reported Outcomes in Patients With Moderate to Severe Plaque Psoriasis in the ESTEEM 1 Trial
1152 Effect of Apremilast on Patient-Reported Outcomes in Patients With Moderate to Severe Plaque Psoriasis in the ESTEEM 1 Trial April W. Armstrong, MD, MPH 1 ; Christopher E.M. Griffiths, MD 2 ; Tom
More informationJEADV SHORT REPORT. Abstract
DOI: 1.1111/jdv.14738 JEADV SHORT REPORT Safety and efficacy of through 14 weeks in patients with moderate to severe psoriasis who continued on or switched from etanercept treatment: findings from the
More informationThe reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment
Original papers The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment Agnieszka Bożek A F, Adam Reich A F Department
More informationFirst Real-World Insights on Apremilast Therapy for Patients With Plaque Psoriasis From the LAPIS-PSO Study: An Interim Analysis
5137 First Real-World Insights on Apremilast Therapy for Patients With Plaque Psoriasis From the Study: An Interim Analysis Kristian Reich, MD 1 ; Stefanie Bomas, MD 2 ; Bernhard Korge, MD 3 ; Maria Manasterski,
More informationQUALITY OF LIFE AMONG ADULT PATIENTS WITH PSORIASIS
e-poster No. P2498 22 nd World Congress of Dermatology, Seoul 2011 QUALITY OF LIFE AMONG ADULT PATIENTS WITH PSORIASIS A study using data from the Malaysian Psoriasis Registry Choong-Chor Chang 1, Felix
More informationInitiation and evaluation of the effect of biologic treatment. ActaDV ActaDV
CLINICAL REPORT 1 Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab Jeanette Halskou HESSELVIG, Alexander EGEBERG,
More informationTranslating Knowledge of IL-23 Targeting into New Solutions for Psoriasis Treatment
Translating Knowledge of IL-23 Targeting into New Solutions for Psoriasis Treatment This symposium took place on 12 th October 2018, as part of the 2 nd European Workshop on Skin Immune Mediated Inflammatory
More informationQuality of Health Care of Rosacea in Germany from the Patient s Perspective: Results of the National Health Care Study RosaReal 2009
Original Paper DOI: 10.1159/000330555 Received: December 20, 2010 Accepted after revision: June 18, 2011 Published online: September 5, 2011 Quality of Health Care of Rosacea in Germany from the Patient
More information75th AAD Annual Meeting
75th AAD Annual Meeting Poster nº 4873 A phase 3 randomized, double-blind, trial comparing the efficacy and safety of the fixed combination calcipotriene 0.005% (Cal) and betamethasone dipropionate 0.064%
More informationCOD. Summary. Contact Dermatitis. Magnus Lindberg 1,2, Kerstin Bingefors 3, Birgitta Meding 4 and Mats Berg 5,6
Contact Dermatitis Original Article COD Contact Dermatitis Hand eczema and health-related quality of life; a comparison of EQ-5D and the Dermatology Life Quality Index (DLQI) in relation to the hand eczema
More informationPatients Perspective on the Impact of Moderate-to-Severe Genital Psoriasis
4664 Patients Perspective on the Impact of Moderate-to-Severe Genital Psoriasis Jennifer Clay Cather, 1 Alison Potts Bleakman, 2 April Naegeli, 2 Jiat Ling Poon, 3 Ashley Wallace, 4 Kristin Hollister,
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Impact of Psoriasis Area and Severity Index (PASI) on patient reported outcomes in patients with psoriasis: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3,
More informationThere is a high prevalence of skin. Quality of Life in Patients with Skin Diseases on Exposed Parts -A Study in Two Teaching Hospitals of Lahore
Proceeding S.Z.P.G.M.I. Vol: 31(2): pp. 103-110, 2017 Quality of Life in Patients with Skin Diseases on Exposed Parts -A Study in Two Teaching Hospitals of Lahore 1 Hadia Shahbaz, 1 Sumbal Shabbir, 2 Jawaria
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. doi: /bjd.
Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory The Harvard community has made
More informationAssociation between disease severity and body mass index in psoriasis patients enrolled in the Corrona Psoriasis Registry
4385 Association between disease severity and body mass index in psoriasis patients enrolled in the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Jeffrey D Greenberg 3,4,
More information(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4
More informationSuperiority in quality of life improvement of biologics over conventional systemic drugs in a swiss real-life psoriasis registry
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2017 Superiority in quality of life improvement of biologics over conventional
More informationBody Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab
Am J Clin Dermatol (16) 17:691 699 DOI 1.7/s257-16-229-x ORIGINAL RESEARCH ARTICLE Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab April
More informationFactor Analysis of the Beer Sheva Psoriasis Severity Score (BPSS)
Factor Analysis of the Beer Sheva Psoriasis Severity Score (BPSS) Arnon D. Cohen MD MPH 1,2,3, Dina Van-Dijk PhD 2, Lechaim Naggan MD 3 and Daniel A. Vardy MD MSc 1,2,4 1 Dermatology Service, Clalit Health
More informationJEADV ORIGINAL ARTICLE. Abstract
DOI: 1.1111/jdv.14878 JEADV ORIGINAL ARTICLE Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-tosevere psoriasis through 5 years of treatment (SCULPTURE
More informationQuality of life in women with female pattern hair loss and the impact of topical minoxidil treatment on quality of life in these patients
542 Quality of life in women with female pattern hair loss and the impact of topical minoxidil treatment on quality of life in these patients XIAO-SHENG ZHUANG, YOU-YOU ZHENG, JIA-JIA XU and WEI-XIN FAN
More informationINVESTIGATIVE REPORT MATERIALS AND METHODS
Acta Derm Venereol 2011; 91: 409 414 INVESTIGATIVE REPORT Are Treatment Satisfaction, Quality of Life, and Self-assessed Disease Severity Relevant Parameters for Patient Registries? Experiences from Finnish
More informationThe Burden of Atopic Dermatitis: from Population to Bedside
The Burden of Atopic Dermatitis: from Population to Bedside S028 AAD Annual Meeting March 2, 2019 Research and institutional funding Sanofi Regeneron Disclosures Consultant Honoraria Sanofi Astellas Canada
More informationAbstract Background: Methods: Results: Conclusion:
1131 Efficacy of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Palmoplantar Psoriasis in Patients With Moderate to Severe Plaque Psoriasis in Phase 2 and Phase 3 (ESTEEM) Trials Robert Bissonnette,
More informationInsights from the Kaiser Permanente database
Insights from the Kaiser Permanente database Jashin J. Wu, M.D. Founding Director of Dermatology Research Director, Psoriasis Clinic Department of Dermatology Kaiser Permanente Los Angeles Medical Center
More informationKey Words: Multidimensional assessment, Psoriasis area severity index, Psoriasis disability index, Psoriasis life stress inventory, Quality of life
Original Article Quality of life in psoriasis: A study from south India S. V. Rakhesh, Mariette D Souza 1, Ajith Sahai 2 Department of Dermatology and STD, Academy of Medical Sciences, Kannur, Kerala;
More informationUC Davis Dermatology Online Journal
UC Davis Dermatology Online Journal Title Palmoplantar pustulosis a cross-sectional analysis in Germany Permalink https://escholarship.org/uc/item/0h15613d Journal Dermatology Online Journal, 23(4) ISSN
More informationPsoriasis Disease Severity Affects Patient Satisfaction With Therapy
82 Psoriasis Disease Severity Affects Patient Satisfaction With Therapy Korman NJ 1, Zhao Y 2, Tran MH 2, Lu J 2 (Please see authors affiliations on the last panel) Background Psoriasis is a chronic, immune
More informationPatient Reported Quality of Life in an Early Psoriatic Arthritis Cohort
26 Patient Reported Quality of Life in an Early Psoriatic Arthritis Cohort Majed Khraishi 1 2, Jennifer Hulburt, Sarah Khraishi and Courtney Youden 2 1 Memorial University of Newfoundland, St. John s,
More informationComparison of Treatment Goals for Moderate-to-Severe Psoriasis between Korean Dermatologists and the European Consensus Report
SW Youn, et al Ann Dermatol Vol. 27, No. 2, 2015 http://dx.doi.org/10.5021/ad.2015.27.2.184 ORIGINAL ARTICLE Comparison of Treatment Goals for Moderate-to-Severe Psoriasis between Korean Dermatologists
More informationBody Surface Area (BSA)
Body Surface Area (BSA) BSA is a commonly used measure of severity of skin disease Defined as the percentage of the total body surface area affected by psoriasis Handprint Method Most common method in
More informationThe Changing Landscape of Psoriasis: New Horizons for Oral Therapies
The Changing Landscape of Psoriasis: New Horizons for Oral Therapies This symposium took place on 14 th September 2017, as part of the 26th European Academy of Dermatology and Venerology (EADV) Congress
More informationRetrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS FUTURE study)
Original Article Submitted: 29.5.2015 Accepted: 26.8.2015 DOI: 10.1111/ddg.12687 Retrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS
More informationPRURI. meter Prof. Dr. med. Matthias Augustin Prof. Dr. med. Marc A. Radtke Prof. Dr. med. Dr. h.c. Sonja Ständer
PRURI meter Prof. Dr. med. Matthias Augustin Prof. Dr. med. Marc A. Radtke Prof. Dr. med. Dr. h.c. Sonja Ständer PRURITUS in Psoriasis Facts Epidemiology 90% of psoriasis patients report pruritus To be
More informationKeywords: Arabic version, Psoriasis Disability Index, psoriasis
Original article 143 Reliability and validity of the Arabic version of the Psoriasis Disability Index questionnaire Hatem M. Zedan a, Hisham D. Gaber a, Ahmed K. Ibrahim b and Ereny Z. Refaa a Departments
More informationJEADV SHORT REPORT. Abstract
DOI: 1.1111/jdv.13216 JEADV SHORT REPORT HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the
More informationCalcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study
Am J Clin Dermatol (17) 18:5 411 DOI.7/s257-17-258- ORIGINAL RESEARCH ARTICLE Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis
More informationDimethyl Fumarate in Psoriasis Therapy
Dimethyl Fumarate in Psoriasis Therapy This meeting took place on 12 th October 2018, as part of the 2 nd European Workshop on Skin Immune Mediated Inflammatory Diseases (SIMID) in Verona, Italy Speakers:
More informationEfficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis (UNVEIL Phase IV Study)
4892 Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis ( Phase IV Study) Bruce Strober, MD 1 ; Jerry Bagel, MD 2 ; Mark Lebwohl, MD 3 ; Linda Stein Gold, MD 4 ; J. Mark Jackson,
More informationQuality of life in children with psoriasis
Quality of life in children with psoriasis Marieke Seyger Psychodermatologie: het kind centraal Vrijdag 23 januari 2015 AMC Amsterdam Disclosure Has received research grants from / was involved in clinical
More informationJEADV ORIGINAL ARTICLE. Abstract
DOI: 10.1111/jdv.13990 JEADV ORIGINAL ARTICLE Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis
More informationIntroduction , International Society for Pharmacoeconomics and Outcomes Research (ISPOR) /08/
Volume 11 Number 3 2008 VALUE IN HEALTH Patient-Reported Outcomes and Health-Care Resource Utilization in Patients with Psoriasis Treated with Etanercept: Continuous versus Interrupted Treatment Joel M.
More informationKenneth Gordon, 1 Kim A. Papp, 2 Kara Creamer Rice, 3 Mona Trivedi, 3 David H. Collier, 3 Greg Kricorian 3
American Academy of Dermatology 75 th Annual Meeting, Orlando, FL; March 3 7, 2017 Poster 4563 Novel Evaluation of Psoriasis Area and Severity Index (PASI) Data: Distribution of PASI Improvements in a
More informationJEADV SHORT REPORT. Abstract
DOI: 10.1111/jdv.15258 JEADV SHORT REPORT Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled
More informationUstekinumab for the treatment of moderate to severe psoriasis
DOI: 10.3310/hta13suppl3/10 Health Technology Assessment 2009; Vol. 13: Suppl. 3 Ustekinumab for the treatment of moderate to severe psoriasis E Gospodarevskaya, J Picot, K Cooper, E Loveman* and A Takeda
More informationJournal of Nobel Medical College
ISSN: 2091-2331 (PRINT) 2091-234X (ONLINE) Journal of Nobel Medical College Available Online: www.nepjol.info, www.nobelmedicalcollege.com.np Volume 7, Number 1, Issue 12, January-June 2018, 45-49 Original
More informationBJD British Journal of Dermatology. Summary. What s already known about this topic? GENERAL DERMATOLOGY
GENERAL DERMATOLOGY BJD British Journal of Dermatology Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis I.Y.K. Iskandar id, 1 D.M. Ashcroft,
More informationPatient Preferences for Topical Psoriasis Treatments are Diverse and Difficult to Predict
Dermatol Ther (Heidelb) (2016) 6:273 285 DOI 10.1007/s13555-016-0119-4 ORIGINAL RESEARCH Patient Preferences for Topical Psoriasis Treatments are Diverse and Difficult to Predict Lars Iversen. Henny B.
More informationREVEALING A CLEAR PATH TOWARDS A NEW ERA IN THE MANAGEMENT OF PSORIASIS
REVEALING A CLEAR PATH TOWARDS A NEW ERA IN THE MANAGEMENT OF PSORIASIS Summary of Presentations from the Novartis-Supported Satellite Symposium, held at the 23 rd EADV Congress, Amsterdam, the Netherlands,
More informationFROM REGISTRY DATA TO REAL-LIFE EXPERIENCES: A HOLISTIC PERSPECTIVE OF PSORIASIS TREATMENT
FROM REGISTRY DATA TO REAL-LIFE EXPERIENCES: A HOLISTIC PERSPECTIVE OF PSORIASIS TREATMENT This symposium took place on 15 th September 2017 as a part of the 26th European Academy of Dermatology and Venereology
More informationHealth Status and Quality of Life in Patients with Psoriasis: An Iranian Cross-Sectional Survey
Original Article Health Status and Quality of Life in Patients with Psoriasis: An Iranian Cross-Sectional Survey Mahshid Moradi MSc 1, Fanni Rencz MD 1,2 1, Ahmad Moradi MD 3, Orsolya Balogh PhD 1, László
More informationDepression and quality of life in psoriasis and psoriatic arthritis patients
Original Article Depression and quality of life in psoriasis and psoriatic arthritis patients Mahsa Ghajarzadeh, MD 1 Shahrbanoo Kheirkhah, SSRC 2 Maryam Ghiasi, MD 3 Nastaran Hoseini, PHD 4 1. student
More informationApproximately 3% of the US adult population,
Disease Burden and Quality of Life in Psoriasis Patients With and Without Comorbid Psoriatic Arthritis: Results From National Psoriasis Foundation Panel Surveys Emily Edson-Heredia, MPH; Baojin Zhu, PhD;
More informationBJD British Journal of Dermatology. Summary. What s already known about this topic? GENERAL DERMATOLOGY
GENERAL DERMATOLOGY BJD British Journal of Dermatology Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective,
More informationIxekizumab improves patient-reported outcomes up to 52 weeks in bdmard-naïve patients with active psoriatic arthritis (SPIRIT-P1)
RHEUMATOLOGY Original article Rheumatology 2018;57:1777 1788 doi:10.1093/rheumatology/key161 Advance Access publication 25 June 2018 Ixekizumab improves patient-reported outcomes up to 52 weeks in bdmard-naïve
More informationCitation for the original published paper (version of record):
http://www.diva-portal.org Preprint This is the submitted version of a paper published in British Journal of Dermatology. Citation for the original published paper (version of record): Hjalte, F., Steen
More informationCLINICAL REPORT. Dynamic Pruritus Score: Evaluation of the Validity and Reliability of a New Instrument to Assess the Course of Pruritus
230 CLINICAL REPORT Dynamic Pruritus Score: Evaluation of the Validity and Reliability of a New Instrument to Assess the Course of Pruritus Sonja STÄNDER 1, Christine BLOME 2, Zografia ANASTASIADOU 2,
More informationReliability and validity of the Chinese version of the Psoriasis Disability Index (PDI) in Chinese patients with psoriasis
He et al. Health and Quality of Life Outcomes 2012, 10:37 RESEARCH Open Access Reliability and validity of the Chinese version of the Psoriasis Disability Index (PDI) in Chinese patients with psoriasis
More informationEffectiveness of Interdisciplinary vs. Dermatological Care of Moderateto-severe Psoriasis: A Pragmatic Randomised Controlled Trial
Acta Derm Venereol 2014; 94: 192 197 CLINICAL REPORT Effectiveness of Interdisciplinary vs. Dermatological Care of Moderateto-severe Psoriasis: A Pragmatic Randomised Controlled Trial Jochen Schmitt 1,2,
More informationTHE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
More informationReceived: June 29, 2006 Revised: August 15, 2006 Accepted: August 30, 2006
Quality J Microbiol of life Immunol in atopic Infect. dermatitis patients 7;4:6-64 Quality of life in atopic dermatitis patients Original Article Habibeh Mozaffari, Zahra Pourpak,, Sara Pourseyed, Abolhasan
More informationrange of factors such as climatic condition, geographical location, genetic makeover, hygienic standards, age,
ISSN: 0975-766X CODEN: IJPTFI Available Online through Research Article www.ijptonline.com PATTERN OF SKIN DISEASES IN SOUTH INDIA AND THEIR EFFECT ON PATIENTS QUALITY OF LIFE C.Anirudh Jagannadh *, D.Rajeev
More informationRecalcitrant Warty Erythroderma With Severe Pruritus. Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University
Recalcitrant Warty Erythroderma With Severe Pruritus Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY Gil Yosipovitch,
More informationAbstract Background: Methods: Results: Conclusion:
1055 Two-Year Safety of, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Psoriasis: Results From a Phase 3, Randomized, Controlled Trial () Kim A. Papp, MD 1 ; Kristian Reich,
More information5 European S3-Guidelines on the Systemic Treatment of Psoriasis Vulgaris
87 5 European S3-Guidelines on the Systemic Treatment of Psoriasis Vulgaris Supported by the EDF/EADV/IPC Pathirana, D.; Ormerod, A. D.; Saiag, P.; Smith, C.; Spuls, P. I.; Nast, A.; Barker, J.; Bos, J.
More informationComparison of four methods for assessment of severity of hand eczema Agner, Tove; Jungersted, Jacob Mutanu; Coenraads, Pieter-Jan; Diepgen, Thomas
University of Groningen Comparison of four methods for assessment of severity of hand eczema Agner, Tove; Jungersted, Jacob Mutanu; Coenraads, Pieter-Jan; Diepgen, Thomas Published in: CONTACT DERMATITIS
More informationQuality of Life of Saudi Patients with Dermatologic Disorders
Clinical Medicine and Diagnostics 2018, 8(1): 1-6 DOI: 10.5923/j.cmd.20180801.01 Quality of Life of Saudi Patients with Dermatologic Disorders Bassam Ahmed Almutlaq 1, Fatemah Kadhem Aljishi 2, Rawan Ahmed
More informationEconomic Evaluation of Apremilast in the Treatment of Moderate to Severe Psoriasis in the United States
1142 Economic Evaluation of Apremilast in the Treatment of Moderate to Severe Psoriasis in the United States Tom Tencer, PhD 1 ; Zoe Clancy, PharmD, MS 1 ; Vidya Damera, MS 2 ; Frank Zhang MD, MPH 1 ;
More informationSCORAD and PO-SCORAD
SCORAD and PO-SCORAD Tools for assessing atopic eczema MetteDeleuran Department of Dermatology Aarhus University Hospital, Denmark SCORAD and PO-SCORAD Tools for assessing atopic eczema SCORAD: The doctors
More informationBiologics in Psoriasis. Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre
Biologics in Psoriasis Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre Disclosures Consultancy services for Celgene, Centocor, Almirall, Amgen, Pfizer, Philips,
More informationHimmelfarb Health Sciences Library, The George Washington University. Dermatology Faculty Publications
Himmelfarb Health Sciences Library, The George Washington University Health Sciences Research Commons Dermatology Faculty Publications Dermatology 3-1-2017 The Efficacy and Safety of, and in Patients with
More informationTreatment Changes in PaMents with Moderate-to- Severe Psoriasis: A RetrospecMve Chart Review
Treatment Changes in PaMents with Moderate-to- Severe Psoriasis: A RetrospecMve Chart Review 4052 Jaclyn A. Smith 1, BS, Brooke Wehausen 1, BS, Irma Richardson 1, MHA, Yang Zhao 4, PhD, Yunfeng Li 4, PhD,
More informationUniversity of California, San Diego, School of Medicine, La Jolla, CA, USA; 2
2194 Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial
More informationNIH Public Access Author Manuscript J Am Acad Dermatol. Author manuscript; available in PMC 2015 December 01.
NIH Public Access Author Manuscript Published in final edited form as: J Am Acad Dermatol. 2014 December ; 71(6): 1167 1175. doi:10.1016/j.jaad.2014.08.003. Comparative Effectiveness of Less Commonly Used
More informationMOR106, an anti-il-17c mab, a potential new approach for treatment of moderate-tosevere atopic dermatitis: Phase 1 study
, an anti-il-17c mab, a potential new approach for treatment of moderate-tosevere atopic dermatitis: Phase 1 study Diamant Thaçi 1, Maria Magdalena Constantin 2, Bernadette Rojkovich 3, Helen Timmis 4,
More informationUC Davis Dermatology Online Journal
UC Davis Dermatology Online Journal Title Increased severity of itching, pain, and scaling in psoriasis patients is associated with increased disease severity, reduced quality of life, and reduced work
More informationGenital Psoriasis Awareness Program: Physical and Psychological Care for Patients with Genital Psoriasis
Acta Derm Venereol 2015; 95: 211 216 CLINICAL REPORT Genital Psoriasis Awareness Program: Physical and Psychological Care for Patients with Genital Psoriasis Kim A. P. Meeuwis 1,2, Joanne A. de Hullu 2,
More informationDevelopments in Psoriasis Management Celgene Corporation 07/14 USII-CELG140030
Developments in Psoriasis Management 2014 Celgene Corporation 07/14 USII-CELG140030 Psoriasis (PsO) Is a Chronic Inflammatory Disease That Can Impact Patients Health-Related Quality of Life PsO is a chronic
More informationBJD. Summary. British Journal of Dermatology THERAPEUTICS
THERAPEUTICS BJD British Journal of Dermatology Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized
More informationJ of Evolution of Med and Dent Sci/ eissn , pissn / Vol. 4/ Issue 70/ Aug 31, 2015 Page 12246
RELATIONSHIP BETWEEN TYPES OF FACIAL PSORIASIS WITH DLQI AND SEVERITY OF PSORIASIS: A STUDY Murugan S 1, Adikrishnan S 2, Rahul Sharma 3, Trishna Vaishali M 4, Krishnakanth M 5, Sudha R 6, Anandan S 7,
More informationPGA x BSA as a PASI Surrogate
PGA x BSA as a PASI Surrogate Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan Hospital New York, NY, USA DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY
More informationEfficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT
Original Paper Received: March 7, 2016 Accepted after revision: October 3, 2016 Published online: January 12, 2017 Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry
More information1 Introduction. Kim A. Papp 1 April W. Armstrong. Wendell Valdecantos 4
Am J Clin Dermatol (216) 17:79 86 DOI 1.17/s4257-15-161-5 ORIGINAL RESEARCH ARTICLE Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis
More informationFormulary Decisions and the Evolution of Psoriasis Treatment
perspectives Formulary Decisions and the Evolution of Psoriasis Treatment William Malatestinic, PharmD, MBA; 1 David Amato, MD; 1 Steven R. Feldman, MD, PhD 2 affiliations: 1 Eli Lilly and Company, Indianapolis,
More informationOmalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria
DOI: 1.1111/jdv.14384 JEADV ORIGINAL ARTICLE Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria A.Y. Finlay, 1, * A.P. Kaplan, 2 L.A. Beck,
More informationThe Natural History of Psoriasis and Treatment Goals
The Natural History of Psoriasis and Treatment Goals Psoriasis Epidemiology Prevalence Affects 2 3% of adult population (>7 million in US) Caucasians: 25% 2.5% African Americans: 1.3% (more likely to have
More informationAtopic Dermatitis: Emerging therapies. Melinda Gooderham MSc MD FRCPC
Atopic Dermatitis: Emerging therapies Melinda Gooderham MSc MD FRCPC SKiN Centre for Dermatology, Peterborough Assistant Professor, Queen s University, Kingston ON Investigator, Probity Medical Research,
More informationContinuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis
DOI: 1.1111/jdv.14163 JEADV ORIGINAL ARTICLE Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis A. Blauvelt, 1, * K.A.Papp, 2 H. Sofen,
More informationEffects of Acupuncture on Chinese Adult Patients with Psoriatic Arthritis: A Prospective Cohort Study
Effects of Acupuncture on Chinese Adult Patients with Psoriatic Arthritis: A Prospective Cohort Study Peiyi Chen 1, Tiantian Xin 2* and Yingchun Zeng 3,4 1 School of Nursing, Guangzhou University of Chinese
More informationValidation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire
Dauden et al. Health and Quality of Life Outcomes 2012, 10:56 RESEARCH Open Access Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire Esteban Dauden
More informationUse of medical record databases to study psoriasis
Use of medical record databases to study psoriasis Joel M. Gelfand, MD, MSCE Professor of Dermatology and Epidemiology Vice Chair for Clinical Research Medical Director, Clinical Studies Unit Director,
More information